Free Trial
NASDAQ:UNCY

Unicycive Therapeutics 3/28/2024 Earnings Report

Unicycive Therapeutics logo
$0.59 0.00 (-0.34%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$0.58 0.00 (-0.51%)
As of 05/30/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Unicycive Therapeutics Earnings Headlines

Q2 Earnings Estimate for UNCY Issued By HC Wainwright
Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile

More Earnings Resources from MarketBeat